Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling ...

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334 (5):296-301. doi: 10.1056/NEJM199602013340504 ...

Virtual echocardiography screening tool scores calculated via algorithm matched manually calculated scores and are promising ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.

Pulmonary hypertension is elevated blood pressure that occurs exclusively in the lungs. It is a deadly condition that affects an estimated 75 million people worldwide. Around 80% of them live in ...

Cite this: Patrice Wendling. Pulmonary Artery Denervation Takes Next Step in Hypertension - Medscape - Sep 18, 2022. Authors and Disclosures Authors and Disclosures Author (s) ...

Ann Intern Med. 2005;143:282-292. 5. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131:657-663. 6.

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints. On Monday, the pharmaceutical company said it has received positive topline results ...

- Conference call and webcast with guest pulmonary key opinion leaders to be held today, Monday, January 27th at 5:00 p.m. EST - January 27, 2020 04:01 PM Eastern Standard Time ...